Unique ganglioside binding by botulinum neurotoxins C and D-SA

FEBS Journal

Volumn 278, Issue 23, 2011, Pages 4486-4496

  Kroken, Abby R ^a   Karalewitz, Andrew P A ^a   Fu, Zhuji ^a   Baldwin, Michael R ^b   Kim, Jung Ja P ^a   Barbieri, Joseph T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

botulinum neurotoxin; gangliosides; host receptors; neurons; synaptic vesicles

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN D; BOTULINUM TOXIN E; BOTULINUM TOXIN F; GANGLIOSIDE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING SITE; BOTULISM; DRUG PROTEIN BINDING; HUMAN; INFECTION PREVENTION; LIPID ANALYSIS; MEMBRANE BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SEQUENCE ALIGNMENT; SEROTYPE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXIN STRUCTURE; VACCINATION; VACCINE PRODUCTION;

BINDING SITES; BOTULINUM TOXINS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; GANGLIOSIDES; MODELS, MOLECULAR; NEUROTOXINS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 81555216752     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08166.x     Document Type: Review

References (71)

1. Gill DM, (1982) Bacterial toxins: a table of lethal amounts. Microbiol Mol Biol Rev 46, 86-94. (Pubitemid 12101491)
2. Singh BR, Gimenez JA, &, DasGupta BR, (1991) Comparative molecular topography of botulinum neurotoxins from Clostridium butyricum and Clostridium botulinum type E. Biochim Biophys Acta 1077, 119-126.
3. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, et al. (2007) Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 189, 818-832. (Pubitemid 46183856)
4. Lacy DB, Tepp W, Cohen AC, DasGupta BR, &, Stevens RC, (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Mol Biol 5, 898-902. (Pubitemid 28467413)
5. Breidenbach MA, &, Brunger AT, (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925-929. (Pubitemid 40037157)
6. Swaminathan S, &, Eswaramoorthy S, (2000) Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Mol Biol 7, 693-699. (Pubitemid 30636683)
7. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, &, Montal M, (2008) Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem 283, 3997-4003.
8. Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, &, Swaminathan S, (2009) Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J Mol Biol 386, 233-245.
9. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, Camilli PD, Sudhof TC, Niemann H, &, Jahn R, (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365, 160-163. (Pubitemid 23282061)
10. Agarwal R, Schmidt JJ, Stafford RG, &, Swaminathan S, (2009) Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Biol 16, 789-794.
11. Chen S, &, Wan HY, (2010) Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F. Biochem J 433, 277-284.
12. Agarwal R, &, Swaminathan S, (2008) SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E. J Biol Chem 283, 25944-25951.
13. Chen S, &, Barbieri JT, (2009) Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci USA 106, 9180-9184.
14. Fischer A, &, Montal M, (2007) Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci USA 104, 10447-10452. (Pubitemid 47185685)
15. Fischer A, Mushrush DJ, Lacy DB, &, Montal M, (2008) Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog 4, e1000245.
16. Koriazova LK, &, Montal M, (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Mol Biol 10, 13-18. (Pubitemid 36034171)
17. Lacy DB, &, Stevens RC, (1997) Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Protein Expr Purif 11, 195-200. (Pubitemid 27498908)
18. Halpern JL, &, Loftus A, (1993) Characterization of the receptor-binding domain of tetanus toxin. J Biol Chem 268, 11188-11192. (Pubitemid 23162310)
19. Umland TC, Wingert LM, Swaminathan S, Furey WF, Schmidt JJ, &, Sax M, (1997) Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat Struct Mol Biol 4, 788-792.
20. Herreros J, Lalli G, &, Schiavo G, (2000) C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem J 347, 199-204. (Pubitemid 30199058)
21. Sharma S, Zhou Y, &, Singh BR, (2006) Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A. Protein Expr Purif 45, 288-295. (Pubitemid 43120433)
22. Lalli G, Herreros J, Osborne S, Montecucco C, Rossetto O, &, Schiavo G, (1999) Functional characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 112, 2715-2724. (Pubitemid 29429794)
23. Emsley P, Fotinou C, Black I, Fairweather NF, Charles IG, Watts C, Hewitt E, &, Isaacs NW, (2000) The structures of the HC fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J Biol Chem 275, 8889-8894. (Pubitemid 30180245)
24. Fotinou C, Emsley P, Black I, Ando H, Ishida H, Kiso M, Sinha KA, Fairweather NF, &, Isaacs NW, (2001) The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J Biol Chem 276, 32274-32281.
25. Jin R, Rummel A, Binz T, &, Brunger AT, (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095. (Pubitemid 46018531)
26. Rummel A, Mahrhold S, Bigalke H, &, Binz T, (2004) The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51, 631-643. (Pubitemid 38233933)
27. Stenmark P, Dupuy J, Imamura A, Kiso M, &, Stevens RC, (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog 4, e1000129.
28. Chen C, Fu Z, Kim J-JP, Barbieri JT, &, Baldwin MR, (2009) Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem 284, 26569-26577.
29. Jayaraman S, Eswaramoorthy S, Kumaran D, &, Swaminathan S, (2005) Common binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin. Proteins 61, 288-295. (Pubitemid 41429136)
30. Montecucco C, (1986) How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 11, 314-317.
31. Nishiki T-i, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sato K, Sekiguchi M, Takahashi M, &, Kozaki S, (1996) The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 378, 253-257.
32. Nishiki T-i, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sekiguchi M, Takahashi M, &, Kozaki S, (1996) Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci Lett 208, 105-108. (Pubitemid 26128119)
33. Kozaki S, Kamata Y, Watarai S, Nishiki T-i, &, Mochida S, (1998) Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog 25, 91-99. (Pubitemid 28398979)
34. Nishiki T, Kamata Y, Nemoto Y, Omori A, Ito T, Takahashi M, &, Kozaki S, (1994) Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 269, 10498-10503. (Pubitemid 24198248)
35. Rummel A, Karnath T, Henke T, Bigalke H, &, Binz T, (2004) Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem 279, 30865-30870. (Pubitemid 38938022)
36. Simpson LL, (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212, 16-21. (Pubitemid 10131942)
37. Hughes R, &, Whaler BC, (1962) Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparation by Cl. botulinum type A toxin. J Physiol 160, 221-233.
38. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, &, Chapman ER, (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162, 1293-1303. (Pubitemid 37210885)
39. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, &, Chapman ER, (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596.
40. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, &, Chapman ER, (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19, 5226-5237.
41. Fu Z, Chen C, Barbieri JT, Kim J-JP, &, Baldwin MR, (2009) Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48, 5631-5641.
42. Baldwin MR, &, Barbieri JT, (2007) Association of botulinum neurotoxin serotypes A and B with synaptic vesicle protein complexes. Biochemistry 46, 3200-3210. (Pubitemid 46449141)
43. Bennett MK, Calakos N, Kreiner T, &, Scheller RH, (1992) Synaptic vesicle membrane proteins interact to form a multimeric complex. J Cell Biol 116, 761-775.
44. Südhof TC, (2004) The synaptic vesicle cycle. Annu Rev Neurosci 27, 509-547. (Pubitemid 39050412)
45. Strotmeier J, Lee K, Völker AK, Mahrhold S, Zong Y, Zeiser J, Zhou J, Pich A, Bigalke H, Binz T, et al. (2010) Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem J 431, 207-216.
46. Tsukamoto K, Kohda T, Mukamoto M, Takeuchi K, Ihara H, Saito M, &, Kozaki S, (2005) Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. J Biol Chem 280, 35164-35171.
47. Rummel A, Hafner K, Mahrhold S, Darashchonak N, Holt M, Jahn R, Beermann S, Karnath T, Bigalke H, &, Binz T, (2009) Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J Neurochem 110, 1942-1954.
48. Oguma K, Yokota K, Hayashi S, Takeshi K, Kumagai M, Itoh N, Tachi N, &, Chiba S, (1990) Infant botulism due to Clostridium botulinum type C toxin. Lancet 336, 1449-1450.
49. Gangarosa EJ, Donadio JA, Armstrong RW, Meyer KF, Brachman PS, &, Dowell VR, (1971) Botulism in the United States, 1899-1969. Am J Epidemiol 93, 93-101.
50. Coffield JA, Bakry N, Zhang RD, Carlson J, Gomella LG, &, Simpson LL, (1997) In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J Pharmacol Exp Ther 280, 1489-1498. (Pubitemid 27166748)
51. Neimanis A, Gavier-Widen D, Leighton F, Bollinger T, Rocke T, &, Morner T, (2007) An outbreak of type C botulism in herring gulls (Larus argentatus) in southeastern Sweden. J Wildl Dis 43, 327-336. (Pubitemid 47342976)
52. Davletov B, Bajohrs M, &, Binz T, (2005) Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci 28, 446-452. (Pubitemid 40982558)
53. Brand CJ, Schmitt SM, Duncan RM, &, Cooley TM, (1988) An outbreak of type E botulism among common loons (Gavia immer) in Michigan's upper peninsula. J Wildl Dis 24, 471-476.
54. Oguma K, Iida H, Shiozaki M, &, Inoue K, (1976) Antigenicity of converting phages obtained from Clostridium botulinum types C and D. Infect Immun 13, 855-860.
55. Simpson LL, &, Rapport MM, (1971) Ganglioside inactivation of botulinum toxin. J Neurochem 18, 1341-1343.
56. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, &, Smith LA, (2007) Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25, 4273-4282. (Pubitemid 46635938)
57. Moriishi K, Syuto B, Kubo S, &, Oguma K, (1989) Molecular diversity of neurotoxins from Clostridium botulinum type D strains. Infect Immun 57, 2886-2891. (Pubitemid 19212628)
58. Oguma K, Syuto B, Agui T, Iida H, &, Kubo S, (1981) Homogeneity and heterogeneity of toxins produced by Clostridium botulinum type C and D strains. Infect Immun 34, 382-388. (Pubitemid 12117535)
59. Oguma K, Syuto B, Iida H, &, Kubo S, (1980) Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains. Infect Immun 30, 656-660. (Pubitemid 11199557)
60. Moriishi K, Koura M, Abe N, Fujii N, Fujinaga Y, Inoue K, &, Ogumad K, (1996) Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochim Biophys Acta 1307, 123-126.
61. Karalewitz AP, Kroken AR, Fu Z, Baldwin MR, Kim JJ, &, Barbieri JT, (2010) Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 49, 8117-8126.
62. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, &, Stevens RC, (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-1100. (Pubitemid 46018532)
63. Tsukamoto K, Kozai Y, Ihara H, Kohda T, Mukamoto M, Tsuji T, &, Kozaki S, (2008) Identification of the receptor-binding sites in the carboxyl-terminal half of the heavy chain of botulinum neurotoxin types C and D. Microb Pathog 44, 484-493.
64. Kalandakanond S, &, Coffield JA, (2001) Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue. J Pharmacol Exp Ther 296, 749-755. (Pubitemid 32187343)
65. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, &, De Grandis D, (1997) Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 224, 91-94. (Pubitemid 27122178)
66. Aoki KR, Smith LA, &, Atassi MZ, (2010) Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 30, 167-187.
67. Smith LA, Jensen MJ, Montgomery VA, Brown DR, Ahmed SA, &, Smith TJ, (2004) Roads from vaccines to therapies. Mov Disord 19 (Suppl 8), S48-S52. (Pubitemid 38967511)
68. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, &, Barbieri JT, (2008) Subunit vaccine against the seven serotypes of botulism. Infect Immun 76, 1314-1318. (Pubitemid 351428096)
69. Dolimbek BZ, Steward LE, Aoki KR, &, Atassi MZ, (2008) Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol Immunol 45, 910-924. (Pubitemid 350016344)
70. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, &, Atassi MZ, (2007) Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 44, 1029-1041. (Pubitemid 44414991)
71. Qazi O, Sesardic D, Tierney R, Soderback Z, Crane D, Bolgiano B, &, Fairweather N, (2006) Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect Immun 74, 4884-4891. (Pubitemid 44157276)